JUNO THERAPEUTICS
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
JUNO THERAPEUTICS
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.junotherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 206-696-0703
Email Addresses:
[email protected]
Total Funding:
310 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS DoubleClick.Net Amazon Virginia Region Amazon Route 53
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-07-14 | RedoxTherapies | RedoxTherapies acquired by Juno Therapeutics | N/A |
| 2016-06-22 | Contura | Contura acquired by Juno Therapeutics | N/A |
| 2016-01-11 | AbVitro | AbVitro acquired by Juno Therapeutics | 125 M USD |
| 2015-06-02 | X BODY | X BODY acquired by Juno Therapeutics | 44 M USD |
| 2015-05-12 | Stage Cell Therapeutics | Stage Cell Therapeutics acquired by Juno Therapeutics | 22 M USD |
Investors List
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Juno Therapeutics
Bezos Expeditions
Bezos Expeditions investment in Series B - Juno Therapeutics
Venrock
Venrock investment in Series B - Juno Therapeutics
Alaska Permanent Fund
Alaska Permanent Fund investment in Series B - Juno Therapeutics
Venrock
Venrock investment in Series A - Juno Therapeutics
Bezos Expeditions
Bezos Expeditions investment in Series A - Juno Therapeutics
Alaska Permanent Fund
Alaska Permanent Fund investment in Series A - Juno Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Juno Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-06-11 | JW Therapeutics | Juno Therapeutics investment in Series B - JW Therapeutics | 100 M USD |
| 2018-03-07 | JW Therapeutics | Juno Therapeutics investment in Series A - JW Therapeutics | 90 M USD |
| 2015-05-27 | Editas Medicine | Juno Therapeutics investment in Funding Round - Editas Medicine | 47 M USD |
Newest Events participated
Official Site Inspections
http://www.junotherapeutics.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Juno Therapeutics"
Juno Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 206-696-0703 Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan …See details»
Juno Therapeutics Company Profile 2024: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Juno Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Juno Therapeutics, Inc. Company Overview, Contact Details
Aug 5, 2014 Juno Therapeutics, Inc. Biotechnology Research Washington, United States 501-1000 Employees. We have merged with Bristol Myers Squibb creating a leading biopharma …See details»
JUNO THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for JUNO THERAPEUTICS, INC. of Cambridge, MA. Get the latest business insights from Dun & …See details»
Juno Therapeutics, Inc. | LinkedIn
Juno Therapeutics, Inc. | 27,751 followers on LinkedIn. We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and …See details»
Juno Therapeutics Company Profile - Craft
Juno Therapeutics $111.87 m in annual revenue in FY 2017. See insights on Juno Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Juno Therapeutics - Company Profile - Tracxn
Dec 1, 2024 Juno Therapeutics - CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer.. Acquired by Celgene. Raised a total funding of $317M over 5 rounds …See details»
Juno Therapeutics - VentureRadar
Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers ' Fred Hutchinson... ... Find out more ...See details»
Juno Therapeutics (USA) Funding: $310M - medicalstartups.org
Dec 10, 2024 Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen …See details»
Juno Therapeutics - Company info. interviews, news
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and …See details»
Juno Therapeutics Inc. | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Juno Therapeutics Revenue, Growth & Competitor Profile
Dec 9, 2024 Revenue: $100 - $500 million See Exact Annual Revenue: Employees: 500 - 1,000 Exact Company Size: Primary Industry: 5417 Scientific Research & Development Services: …See details»
Juno Therapeutics Inc. - The New York Times
I.P.O. of Juno Therapeutics, Developer of a Cancer Treatment, Excites Investors. A little-known year-old company, which counts Jeff Bezos as an early investor, pulled off one of the largest ...See details»
Juno Therapeutics CEO and Key Executive Team | Craft.co
Juno Therapeutics's CEO is Hans Bishop. Other executives include Hyam Levitsky, EVP, Chief Scientific Officer; Steve Harr, CFO & Head of Corporate Development and 4 others. See the …See details»
Juno Therapeutics, Inc. | Reuters
Aug 27, 2021 The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead …See details»
Working at Juno Therapeutics - Glassdoor
Juno Therapeutics is a Celgene Company. Juno is developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and …See details»
Juno’s lasting legacy: How the cell therapy juggernaut influenced ...
Feb 8, 2022 Juno’s success reverberated throughout biotech in Seattle and beyond, fueling interest in cell and gene therapy and providing a blueprint for the next generation of startups …See details»